Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label safety study of atezolizumab in advanced or metastatic urinary tract carcinoma
2016-002625-11Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of atezolizumab in transitional cell carcinoma (TCC), non-urothelial carcinoma of the urinary tract and non-small cell lung cancer (NSCLC), sponsored by Roche. Primary endpoint: Nature, severity, duration, frequency and timing of adverse events. Started Oct 2016; status: completed.
02
Drugs
atezolizumab
03
Conditions
transitional cell carcinoma (TCC)non-urothelial carcinoma of the urinary tractnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2016-002625-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002625-11.